Menu

World’s First Commercial iPSC Cell Plant Opens in Japan

The $340 million, 30,000-square-foot center will produce cells for therapeutic applications.

Mar 23, 2018
Jim Daley

Human induced pluripotent stem cellsCHRISTINE HALE, WIKIMEDIAA pharmaceutical company based in Osaka, Japan, opened a regenerative medicine center yesterday (March 22) that will produce cells derived from induced pluripotent stem (iPS) cells for commercial applications. The center is the first plant of its kind globally. It will initially produce cells for use in clinical trials.

The Sumitomo Dainippon Manufacturing Plant for Regenerative Medicine & Cell Therapy will allow the company to “gain an overwhelming advantage in the market of medical and pharmaceutical products,” Masayo Tada, president of Sumitomo Dainippon Pharma, tells The Asahi Shimbun. “We will occupy a definite position in the field of regenerative medicine.” On April 1, Hiroshi Nomura, currently the company’s executive vice president, will replace Tada as president, according to The Pharma Letter. Tada will transition to the position of chairman.

Existing iPSC production facilities, including the National Institutes of Health’s Center for Regenerative Medicine and WiCell’s Stem Cell Bank, have made cells available to researchers. The Sumitomo Dainippon plant will be the first to offer cells for commercial purposes.

Construction of the center cost approximately 3.6 billion yen ($342.7 million USD), according to a statement. The facility has more than 30,000 square feet of floor space divided among three autonomous zones that will produce different types of cells. Company officials say that each zone will be able to produce enough cells to treat hundreds of patients per year, according to The Asahi Shimbun

The company will use iPS cells produced at Kyoto University’s Center for iPS Cell Research and Application (CiRA) for cell production. Sumitomo Dainippon and CiRA have previously collaborated to develop iPS cell-based regenerative medicine technology for patients with Parkinson's disease.

See “Banking on iPSCs

Sumitomo Dainippon plans to make regenerative medicine one of its core businesses and endeavors to increase sales to 200 billion yen ($1.8 billion USD) by 2030, according to The Asahi Shimbun.

January 2019

Cannabis on Board

Research suggests ill effects of cannabinoids in the womb

Marketplace

Sponsored Product Updates

FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX has announced that their digital PCR assets, including the CONSTELLATION® series of instruments, is being acquired by QIAGEN N.V. (NYSE: QGEN, Frankfurt Stock Exchange: QIA) for up to $260 million ($125 million upfront payment and $135 million of milestones).  QIAGEN has announced plans for a global launch in 2020 of a new series of digital PCR platforms that utilize the advanced dPCR technology developed by FORMULATRIX combined with QIAGEN’s expertise in assay development and automation.
Application of CRISPR/Cas to the Generation of Genetically Engineered Mice
Application of CRISPR/Cas to the Generation of Genetically Engineered Mice
With this application note from Taconic, learn about the power that the CRISPR/Cas system has to revolutionize the field of custom mouse model generation!
Translational Models of Obesity, Dysmetabolism, Diabetes, and Complications
Translational Models of Obesity, Dysmetabolism, Diabetes, and Complications
This webinar, from Crown Bioscience, presents a unique continuum of translational dysmetabolic platforms that more closely mimic human disease. Learn about using next-generation rodent and spontaneously diabetic non-human primate models to accurately model human-relevant disease progression and complications related to obesity and diabetes here!
BiochemAR: an augmented reality app for easy visualization of virtual 3D molecular models
BiochemAR: an augmented reality app for easy visualization of virtual 3D molecular models
Have you played Pokemon Go? Then you've used Augmented Reality (AR) technology! AR technology holds substantial promise and potential for providing a low-cost, easy to use digital platform for the manipulation of virtual 3D objects, including 3D models of biological macromolecules.